Research programme: lung disorders therapy - Beth Israel Deaconess/SELECT Therapeutics
Alternative Names: Lung disorders therapy research programme - Beth Israel Deaconess/SELECT TherapeuticsLatest Information Update: 08 Nov 2002
At a glance
- Originator Beth Israel Deaconess Medical Center; SELECT Therapeutics (CEASED)
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Cystic fibrosis; Respiratory tract disorders
Most Recent Events
- 08 Nov 2002 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 08 Nov 2002 Discontinued - Preclinical for Cystic fibrosis in USA (unspecified route)
- 08 Nov 2002 Discontinued - Preclinical for Respiratory tract disorders in USA (unspecified route)